In the past, persons diagnosed with thrombotic microangioipathies (TMAs) like thrombotic thrombotcytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS) required multiple tests to attempt to determine a genetic cause of their disease. These tests could be expensive, inconvenient and time consuming. Now, The University of Iowa offers the Genetic Renal Panel -- one test that is:
- Comprehensive – tests for all genes known to be associated with a variety of TMAs and complement mediated renal diseases
- Easy – patient provides one blood sample
- Convenient – blood sample is taken in local doctor’s office
- Fast – one test shortens waiting time for results
- Accurate – 99 percent diagnostic specificity
- Pinpointed diagnosis – offers the best method of treatment, prognosis for transplant and genetic counseling
- Less expensive – one test versus many tests
Next Generation Sequencing and Multiple Ligation Probe Amplification (MLPA) of the CFH-CFHR5 genomic region.
Approximately 3 weeks.
8 - 10 cc. whole blood in lavender (EDTA) top tubes OR 10 μg DNA, minimum concentration: 50 ng/μl (A260/A280 1.8-2) resuspended in 0.1mM EDTA (10mM Tris HC1, 0.1mM EDTA, pH 8, Teknova Cat#T0220).
Cost & CPT Codes
See the MORL Testing Menu
Reasons for Testing
Genetic testing for renal disease can provide important answers to many questions. By determining the cause of renal disease, information can be provided on recurrence chance, prognosis (whether a transplant might be successful or what type of transplant is necessary, i.e. kidney only or liver/kidney), and best methods of treatment.